We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Dentsply Sirona is the worldâs largest manufacturer of professional dental produ...
Dentsply Sirona is the worldâs largest manufa...
BIOLASE, Inc. is a medical device company and global market leader in the manufact...
BIOLASE, Inc. is a medical device company and g...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Aurinia is a late clinical stage biopharmaceutical company focused on developing a...
Aurinia is a late clinical stage biopharmaceuti...
Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to address...
Foamix Pharmaceuticals is a specialty pharmaceu...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...
Takeda Pharmaceutical Company Limited (TSE:4502...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Join the National Investor Network and get the latest information with your interests in mind.